Clinical & Experimental Metastasis

, Volume 21, Issue 6, pp 553–561 | Cite as

Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: Effects of α v β 3 and α IIb β 3 antagonists

  • Noëlia Gomes
  • Jany Vassy
  • Claude Lebos
  • Brigitte Arbeille
  • Chantal Legrand
  • Françoise Fauvel-Lafeve


Tumour cell adhesion to vascular extracellular matrix (ECM), an important step of metastatic progression, is promoted by platelets. The aim of our study was to investigate, in whole blood under venous and arterial shear conditions, the respective role of tumour cell αvβ3 and platelet αIIbβ3integrins in MDA-MB-231 breast adenocarcinoma cell adhesion to human umbilical vein endothelial cell ECM. For that purpose, blood containing MDA-MB-231 cells was incubated with non-peptide antagonists specific for platelet αIIbβ3 (lamifiban) or tumour cell αvβ3 (SB-273005). At 300 s−1, each antagonist used alone did not modify tumour cell adhesion, whereas, at 1500 s−1, tumour cell adhesion was decreased by 25% in presence of lamifiban indicating a role of platelet αIIbβ3 at higher shear rate. However, a combination of SB-273005 and lamifiban, or c7E3 Fab (a potent inhibitor of both αIIbβ3 and αvβ3) inhibited tumour cell adhesion by 40–45%, at either shear rate applied, indicating a cooperation between these two integrins in MDA-MB-231 cell adhesion to ECM, as well as the participation of other adhesive receptors on tumour cells and/or platelets. Thus, efficient anti-metastatic therapy should target multiple receptors on tumour cells and platelets.

adhesion extracellular matrix integrin integrin antagonists platelet shear rate tumour cell 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weiss L. Metastatic ine. ciency. Adv Cancer Res 1990; 54: 159–211.PubMedCrossRefGoogle Scholar
  2. 2.
    Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990; 322(9): 605–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Xiong JP, Stehle T, Goodman SL et al. Integrins, cationsand ligands: making the connection. J Thromb Haemost2003; 1(7): 1642–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol 1992; 4(5): 766–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Albelda SM, Mette SA, Elder DE et al. Integrin distributionin malignant melanoma: association of the beta 3 sub uni twith tumor progression. Cancer Res 1990; 50(20): 6757–64.PubMedGoogle Scholar
  6. 6.
    Pignatelli M, Cardillo MR, Hanby A et al. Integrins andtheir accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992; 23(10): 1159–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Ria R, Vacca A, Ribatti D et al. Alpha(v) beta(3) integrinengagement enhances cell invasiveness in human multiplemyeloma. Haematologica 2002; 87(8): 836–45.PubMedGoogle Scholar
  8. 8.
    Horton MA. The alpha v beta integrin 'vitronectin receptor. Int J Biochem Cell Biol 1997; 29(5): 721–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Lawler J, Hynes RO. An integrin receptor on normal andthrombasthenic platelets that binds thrombospondin. Blood 1989; 74(6): 2022–7.PubMedGoogle Scholar
  10. 10.
    Denis C, Williams JA, Lu X et al. Solid-phase von Wille-brand factor contains a conformationally active RGD motifthat mediates endothelial cell adhesion through the alpha vbeta 3 receptor. Blood 1993; 82(12): 3622–30.PubMedGoogle Scholar
  11. 11.
    Karpatkin S, Pearlstein E. Role of platelets in tumor cellmetastases. Ann Intern Med 1981; 95(5): 636–41.PubMedGoogle Scholar
  12. 12.
    Honn KV, Tang DG, Crissman JD. Platelets and cancermetastasis: a causal relationship? Cancer Metastasis Rev 1992; 11(3–4): 325–51.PubMedCrossRefGoogle Scholar
  13. 13.
    Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61(1): 46–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Nieswandt B, Hafner M, Echtenacher B et al. Lysis of tumorcells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59(6): 1295–300.PubMedGoogle Scholar
  15. 15.
    Bastida E, Almirall L, Ordinas A. Platelet and shear rate pro-mote tumor cell adhesion to human endothelial extracellularmatrix–absence of a role for platelet cyclooxygenase. Thromb Haemost 1989; 61(3): 485–9.PubMedGoogle Scholar
  16. 16.
    Dardik R, Kaufmann Y, Savion N et al. Platelets mediatetumor cell adhesion to the subendothelium underflow conditions: involvement of platelet GPIIb-IIIa and tumor cellalpha(v) integrins. Int J Cancer 1997; 70(2): 201–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Parise LV. Integrin alpha(IIb) beta(3) signaling in plateletadhesion and aggregation. Curr Opin Cell Biol 1999; 11(5): 597–601.PubMedCrossRefGoogle Scholar
  18. 18.
    Nierodzik ML, Klepsh A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, bronectin and von Willebrandfactor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995; 74(1): 282–90.PubMedGoogle Scholar
  19. 19.
    Felding-Habermann B, Habermann R, Saldivar E et al. Roleof beta3 integrins in melanoma cell adhesion to activatedplatelets underflow. J Biol Chem 1996; 271(10): 5892–900.PubMedCrossRefGoogle Scholar
  20. 20.
    Felding-Habermann B, O' Toole TE, Smith JW et al. Integrinactivation controls metastasis in human breast cancer. ProcNatl Acad Sci USA 2001; 98(4): 1853–8.CrossRefGoogle Scholar
  21. 21.
    Alig L, Edenhofer A, Hadvary P et al. Low molecular weight, non-peptide brinogen receptor antagonists. J Med Chem 1992; 35(23): 4393–407.PubMedCrossRefGoogle Scholar
  22. 22.
    Miller WH, Alberts DP, Bhatnagar PK et al. Discovery oforally active nonpeptide vitronectin receptor antagonists basedon a 2-benzazepine Gly-Asp mimetic. J Med Chem 2000; 43(1): 22–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Tam SH, Sassoli PM, Jordan RE et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v) beta3 inte-grins. Circulation 1998; 98(11): 1085–91.PubMedGoogle Scholar
  24. 24.
    Coller BS. Platelet GPIIb/IIIa antagonists: The rst anti-inte-grin receptor therapeutics. J Clin Invest 1997; 99(7): 1467–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Incardona F, Calvo F, Fauvel-Lafeve F et al. Involvement ofthrombospondin in the adherence of human breast-adenocarci-noma cells: A possible role in the metastatic process. Int J Cancer 1993; 55(3): 471–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Jae EA, Nachman RL, Becker CG et al. Culture of humanendothelial cells derived from umbilical veins. Identi cation bymorphologic and immunologic criteria. J Clin Invest 1973; 52(11): 2745–56.CrossRefGoogle Scholar
  27. 27.
    Bonnefoy A, Harsfalvi J, Piegler G et al. The subendotheliumof the HMEC-1 cell line supports thrombus formation in theabsence of von Willebrand factor and collagen types I, III andVI. Thromb Haemost 2001; 85(3): 552–9.PubMedGoogle Scholar
  28. 28.
    Murphy NP, Pratico D, Fitzgerald DJ. Functional relevance ofthe expression of ligand-induced binding sites in the response toplatelet GP IIb/IIIa antagonists in vivo. J Pharmacol Exp Ther 1998; 286(2): 945–51.PubMedGoogle Scholar
  29. 29.
    Kuwahara M, Sugimoto M, Tsuji S et al. Comparative studieson the antiplatelet effects of a humanized anti-platelet glycopro-tein IIb/IIIa antibody (YM337) and ReoPro underflow condi-tions. Thromb Haemost 1998; 80(1): 28–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Sakariassen KS, Aarts PA, de Groot PG et al. A perfusionchamber developed to investigate platelet interaction inflowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102(4): 522–35.PubMedGoogle Scholar
  31. 31.
    Lafeve F, Meric A, Arbeille B et al. Spectrophotometric evalua-tion of the adhesion of blood platelets to collagen and micro –brils. Thromb Res 1993; 71(3): 193–204.PubMedCrossRefGoogle Scholar
  32. 32.
    Lacroix M, Leclercq G. Relevance of breast cancer cell lines asmodels for breast tumours: an update. Breast Cancer Res Treat2004; 83(3): 249–89.PubMedCrossRefGoogle Scholar
  33. 33.
    Konstantopoulos K, Kamat SG, Schafer AI et al. Shear-induced platelet aggregation is inhibited by in vivo infusion ofan anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, inpatients undergoing coronary angioplasty. Circulation 1995; 91(5): 1427–31.PubMedGoogle Scholar
  34. 34.
    Goldsmith HL, Turitto VT. Rheological aspects of thrombosisand haemostasis: Basic principles and applications. ICTH-Report–Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb Haemost1986; 55(3): 415–35.PubMedGoogle Scholar
  35. 35.
    Miller WH, Keenan RM, Willette RN et al. Identi cation and in vivo efficacy of small-molecule antagonists of integrinalphavbeta3 (the vitronectin receptor). Drug Discov Today2000; 5(9): 397–48.PubMedCrossRefGoogle Scholar
  36. 36.
    Al-Mehdi AB, Tozawa K, Fisher AB et al. Intravascular originof metastasis from the proliferation of endothelium-attachedtumor cells: A new model for metastasis. Nat Med 2000; 6(1): 100–2.PubMedCrossRefGoogle Scholar
  37. 37.
    Borsig L, Wong R, Feramisco J et al. Heparin and cancer revis-ited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA2001; 98(6): 3352–7.PubMedCrossRefGoogle Scholar
  38. 38.
    van der Pluijm G, Vloedgraven H, Papapoulos S et al. Attach-ment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 1997; 77(6): 665–75.PubMedGoogle Scholar
  39. 39.
    Oleksowicz L, Mrowiec Z, Schwartz E et al. Characterizationof tumor-induced platelet aggregation: The role of immunore-lated GPIb and GPIIb/IIIa expression by MCF-7 breast cancercells. hromb Res 1995; 79(3): 261–74.CrossRefGoogle Scholar
  40. 40.
    Chopra H, Timar J, Rong X et al. Is there a role for the tumorcell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? Clin Exp Metast 1992; 10(2): 125–37.CrossRefGoogle Scholar
  41. 41.
    Pilch J, Habermann R, Felding-Habermann B. Unique abilityof integrin alpha(v) beta 3 to support tumor cell arrest under dynamic flow conditions. J Biol Chem 2002; 277(24): 21930–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8(11): 1227–34.PubMedCrossRefGoogle Scholar
  43. 43.
    Andre P, Arbeille B, Drouet V et al. Optimal antagonism ofGPIIb/IIIa favors platelet adhesion by inhibiting thrombusgrowth. An ex vivo capillary perfusion chamber study in theguinea pig. Arterioscler Thromb Vasc Biol 1996; 16(1): 56–63.PubMedGoogle Scholar
  44. 44.
    Helmke BP, Goldman RD, Davies PF. Rapid displacement of vimentin intermediate laments in living endothelial cells exposed to flow. Circ Res 2000; 86(7): 745–52.PubMedGoogle Scholar
  45. 45.
    Baumgartner HR, Muggli R, Tschopp TB et al. Platelet adhe-sion, release and aggregation in flowing blood: Effects of surface properties and platelet function. Thromb Haemost 1976; 35(1): 124–38.PubMedGoogle Scholar
  46. 46.
    Incardona F, Lawler J, Cataldo D et al. Heparin-bindingdomain, type 1 and type 2 repeats of thrombospondin mediateits interaction with human breast cancer cells. J Cell Biochem 1996; 62(4): 431–42.PubMedCrossRefGoogle Scholar
  47. 47.
    Loganadane LD, Vassy J, Legrand C et al. Transforminggrowth factor-beta 1 increases the adhesion of MDA-MB-231mammary adenocarcinoma cells to the microvascular subendo-thelium. Cell Adhes Commun 1999; 7(1): 57–71.PubMedCrossRefGoogle Scholar
  48. 48.
    Haier J, Nasralla MY, Nicolson GL. Beta1-integrin-mediateddynamic adhesion of colon carcinoma cells to extracellularmatrix under laminar flow. Clin Exp Metast 1999; 17(5): 377–87.CrossRefGoogle Scholar
  49. 49.
    Beauvais DM, Rapraeger AC. Syndecan-1-mediated cell spread-ing requires signaling by alphavbeta3 integrins in human breastcarcinoma cells. Exp Cell Res 2003; 286(2): 219–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Cohen SA, Trikha M, Mascelli MA. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res2000; 6(3): 163–74.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Noëlia Gomes
    • 1
  • Jany Vassy
    • 1
  • Claude Lebos
    • 1
  • Brigitte Arbeille
    • 1
  • Chantal Legrand
    • 1
  • Françoise Fauvel-Lafeve
    • 1
  1. 1.INSERM, U 553 Hémostase, Endothélium et Angiogénèse, IFR 105, Institut d'HématologieUniversité Paris VII Denis Diderot, Hôpital Saint-Louis 1ParisFrance

Personalised recommendations